Lehigh University

Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell

Retrieved on: 
Wednesday, March 6, 2024

EDISON, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, and other chronic diseases, today announced the appointment of Michael Purcell to the Company’s Board of Directors, effective March 5, 2024.

Key Points: 
  • EDISON, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, and other chronic diseases, today announced the appointment of Michael Purcell to the Company’s Board of Directors, effective March 5, 2024.
  • Mr. Purcell has more than 37 years of professional experience with Deloitte & Touche LLP, serving as a consultant from 2015 to 2017 and an Audit Partner from 1979 until 2015.
  • Mr. Purcell also currently serves as a financial advisor to several emerging growth companies.
  • Mr. Purcell has worked on a number of company boards and has served on the Board of Directors of CFG Bank since 2016, the Board of Directors of Hyperion Bank since 2018, and the Board of Directors of International Money Express, Inc. since 2018.

Peapack Private Hires Ron Bezoza as Senior Managing Director - Managing Principal, Head of Sales and Relationship Management

Retrieved on: 
Tuesday, February 27, 2024

BEDMINSTER, NJ, Feb. 27, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - Peapack-Gladstone Financial Corporation (NASDAQ Global Select Market:  PGC) announces the appointment of Ron Bezoza as Senior Managing Director - Managing Principal, Head of Sales and Relationship Management at Peapack Private, a division of Peapack-Gladstone Bank.

Key Points: 
  • BEDMINSTER, NJ, Feb. 27, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - Peapack-Gladstone Financial Corporation (NASDAQ Global Select Market:  PGC) announces the appointment of Ron Bezoza as Senior Managing Director - Managing Principal, Head of Sales and Relationship Management at Peapack Private, a division of Peapack-Gladstone Bank.
  • Mr. Bezoza is also responsible for expanding Peapack Private’s footprint through recruiting and business development.
  • At Morgan Stanley, Ron was Managing Director, Head of Managed Solutions Group and Business Development for the Solutions & Multi-Asset Group at Morgan Stanley in New York, NY.
  • During his 11-year tenure at Goldman Sachs, Ron served as Managing Director and Global Head of Private Wealth Management Equity Solutions Group and played a pivotal role in shaping the mass affluent and high-net-worth client segments.

PulteGroup Nominates Kristen Actis-Grande for Election to Board of Directors

Retrieved on: 
Friday, March 8, 2024

PulteGroup (NYSE: PHM), the nation’s third-largest homebuilder, today announced the nomination of Kristen Actis-Grande, Executive Vice President and Chief Financial Officer of MSC Industrial Direct Co., Inc. (“MSC”) (NYSE: MSM), for election as a new independent director to its Board of Directors (“Board”).

Key Points: 
  • PulteGroup (NYSE: PHM), the nation’s third-largest homebuilder, today announced the nomination of Kristen Actis-Grande, Executive Vice President and Chief Financial Officer of MSC Industrial Direct Co., Inc. (“MSC”) (NYSE: MSM), for election as a new independent director to its Board of Directors (“Board”).
  • Ms. Actis-Grande’s appointment will be effective immediately if elected by PulteGroup shareholders at its annual meeting scheduled for May 6, 2024.
  • “Kristen is a strategic and accomplished business leader, and we are pleased that she is joining PulteGroup's Board," said Thomas J. Folliard, Chairman of the Board of PulteGroup.
  • Actis-Grande holds an MBA from the Indiana University Kelley School of Business and a bachelor’s degree in finance from Lehigh University.

Pharmascience Expands its Contract Development and Manufacturing Organization (CDMO) Services With a New Commercial Business Unit

Retrieved on: 
Monday, February 26, 2024

Following this important milestone, the company is now proud to announce the expansion of its contract development and manufacturing organization (CDMO) services with the creation of a new business unit dedicated to injectable products.

Key Points: 
  • Following this important milestone, the company is now proud to announce the expansion of its contract development and manufacturing organization (CDMO) services with the creation of a new business unit dedicated to injectable products.
  • This new business unit will help accelerate production and achieve Pharmascience's growth objectives by enabling the company to offer its R&D, formulation and manufacturing services to external pharmaceutical partners.
  • It will focus more specifically on injectable products, with a mandate to offer CDMO services to biotech companies and those with complex injectable product development or manufacturing needs.
  • Appointment of John Foy as General Manager, CDMO
    Alongside the creation of this new CDMO business unit, Pharmascience is pleased to welcome John Foy as General Manager, CDMO since February.

Enable Injections Appoints David Kroekel as Chief Operating Officer

Retrieved on: 
Wednesday, February 7, 2024

CINCINNATI, Feb. 7, 2024 /PRNewswire/ -- Enable Injections, Inc. ("Enable"), a leading innovator in developing and manufacturing the enFuse® platform of wearable drug delivery systems, today announced the appointment of David Kroekel, previously Senior Vice President, Product Development and Operations at Enable, to Chief Operating Officer. In this critical position, Mr. Kroekel will play an important role leading the ongoing engineering, manufacturing, and supply of the Company's enFuse technology.

Key Points: 
  • CINCINNATI, Feb. 7, 2024 /PRNewswire/ -- Enable Injections, Inc. ("Enable"), a leading innovator in developing and manufacturing the enFuse® platform of wearable drug delivery systems, today announced the appointment of David Kroekel, previously Senior Vice President, Product Development and Operations at Enable, to Chief Operating Officer.
  • In this critical position, Mr. Kroekel will play an important role leading the ongoing engineering, manufacturing, and supply of the Company's enFuse technology.
  • "David brings a wealth of experience in cross-functional collaboration, infrastructure development, and engineering excellence in medical device manufacturing and development," said Mike Hooven, Chairman and CEO of Enable Injections.
  • I look forward to leading and advancing how our manufacturing and product development teams increase the capabilities and efficiencies in delivering our wearable technology to more patients," said David Kroekel, Chief Operating Officer of Enable Injections.

Enable Injections Appoints David Kroekel as Chief Operating Officer

Retrieved on: 
Wednesday, February 7, 2024

CINCINNATI, Feb. 7, 2024 /PRNewswire/ -- Enable Injections, Inc. ("Enable"), a leading innovator in developing and manufacturing the enFuse® platform of wearable drug delivery systems, today announced the appointment of David Kroekel, previously Senior Vice President, Product Development and Operations at Enable, to Chief Operating Officer. In this critical position, Mr. Kroekel will play an important role leading the ongoing engineering, manufacturing, and supply of the Company's enFuse technology.

Key Points: 
  • CINCINNATI, Feb. 7, 2024 /PRNewswire/ -- Enable Injections, Inc. ("Enable"), a leading innovator in developing and manufacturing the enFuse® platform of wearable drug delivery systems, today announced the appointment of David Kroekel, previously Senior Vice President, Product Development and Operations at Enable, to Chief Operating Officer.
  • In this critical position, Mr. Kroekel will play an important role leading the ongoing engineering, manufacturing, and supply of the Company's enFuse technology.
  • "David brings a wealth of experience in cross-functional collaboration, infrastructure development, and engineering excellence in medical device manufacturing and development," said Mike Hooven, Chairman and CEO of Enable Injections.
  • I look forward to leading and advancing how our manufacturing and product development teams increase the capabilities and efficiencies in delivering our wearable technology to more patients," said David Kroekel, Chief Operating Officer of Enable Injections.

Six New Directors Join Board of Operation Underground Railroad

Retrieved on: 
Tuesday, February 6, 2024

Operation Underground Railroad (“O.U.R.”), a leading non-profit organization dedicated to combating human trafficking, today announced that six accomplished professionals have joined its board of directors.

Key Points: 
  • Operation Underground Railroad (“O.U.R.”), a leading non-profit organization dedicated to combating human trafficking, today announced that six accomplished professionals have joined its board of directors.
  • “It is a privilege to serve on O.U.R.’s board with my fellow directors, who bring a wealth of experience, expertise, and passionate commitment to O.U.R.’s mission of rescuing and supporting victims of trafficking and exploitation,” said Board Chairman Sean Vassilaros.
  • Through her commitment and expertise, she is an essential figure in protecting children from trafficking and other online dangers.
  • Sean is the co-Founder and Chief Executive Officer of KANNY, an innovative software company in the HR Tech space.

SEI Appoints Sean Denham as CFO

Retrieved on: 
Monday, February 5, 2024

OAKS, Pa., Feb. 5, 2024 /PRNewswire/ -- SEI ® (NASDAQ:SEIC) today announced the appointment of Sean Denham as an Executive Vice President and Chief Financial Officer, reporting to CEO Ryan Hicke.

Key Points: 
  • OAKS, Pa., Feb. 5, 2024 /PRNewswire/ -- SEI ® (NASDAQ:SEIC) today announced the appointment of Sean Denham as an Executive Vice President and Chief Financial Officer, reporting to CEO Ryan Hicke.
  • Denham's employment will begin on March 18, 2024, and his appointment as CFO will be effective on the day following the resignation of current CFO Dennis McGonigle, whose departure plans were announced by SEI in July 2023.
  • Denham succeeds McGonigle, who has served in a number of different roles and leadership positions at SEI for nearly 40 years.
  • Sean leads by example and embodies the values that our stakeholders expect from us to the same degree as Dennis.

Stuart Therapeutics Announces Chief Medical and Chief Financial Officer Appointments

Retrieved on: 
Thursday, February 1, 2024

STUART, Fla., Feb. 1, 2024 /PRNewswire/ -- Stuart Therapeutics, Inc. ("Stuart"), a clinical-stage biopharmaceutical company with candidate therapeutics in various phases of clinical development, today announced that it has appointed Jodi Luchs, MD to the position of Chief Medical Officer, and Don Stires to the position of Chief Financial Officer.

Key Points: 
  • STUART, Fla., Feb. 1, 2024 /PRNewswire/ -- Stuart Therapeutics, Inc. ("Stuart"), a clinical-stage biopharmaceutical company with candidate therapeutics in various phases of clinical development, today announced that it has appointed Jodi Luchs, MD to the position of Chief Medical Officer, and Don Stires to the position of Chief Financial Officer.
  • With the appointment of Dr. Luchs, Robert Baratta, MD has stepped aside from his current role as Chief Medical Officer but will continue as Stuart's Executive Chairman of the Board.
  • "Stuart Therapeutics' growth, international operations and increase in pipeline opportunities require an expansion of our team and capabilities," said Eric Schlumpf, President and Chief Executive Officer of Stuart.
  • He completed an internship at the Mount Sinai Medical Center, and his Ophthalmology residency at Long Island Jewish Medical Center.

Mercury Appoints Stuart Kupinsky as Chief Legal Officer

Retrieved on: 
Thursday, January 25, 2024

ANDOVER, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Mercury Systems, Inc. (NASDAQ: MRCY, www.mrcy.com ), a technology company that delivers mission-critical processing power to the edge, today announced the appointment of Stuart Kupinsky as Executive Vice President and Chief Legal Officer, effective Jan. 29, 2024.

Key Points: 
  • ANDOVER, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Mercury Systems, Inc. (NASDAQ: MRCY, www.mrcy.com ), a technology company that delivers mission-critical processing power to the edge, today announced the appointment of Stuart Kupinsky as Executive Vice President and Chief Legal Officer, effective Jan. 29, 2024.
  • Reporting to Mercury Chairman and CEO Bill Ballhaus, Kupinsky will be responsible for the company’s legal strategy, including M&A, intellectual property, and enterprise contracts.
  • Kupinsky was also Chief Counsel for FirstNet, a multibillion-dollar independent government agency building a nationwide network for first responders.
  • “We are excited for Stuart to join the Mercury management team,” said Bill Ballhaus.